Kidney Graft Function in Long-term Cyclosporine and Tacrolimus Treatment: Comparative Study With Nephrotoxicity Markers

Transplantation Proceedings

Volumn 41, Issue 5, 2009, Pages 1660-1665

  Marchewka, Z ^a   Kuzniar J ^a   Zynek Litwin, M ^a   Falkiewicz, K ^a   Szymanska B ^a   Roszkowska, A ^a   Klinger, M ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA GALACTOSIDASE; BETA GLUCURONIDASE; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N ACETYL BETA GLUCOSAMINIDASE; N ACETYL BETA GLUCOSAMINIDASE B; PREDNISONE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RECIPIENT; SURGICAL PATIENT; TREATMENT DURATION; URINALYSIS;

ACETYLGLUCOSAMINIDASE; ADULT; AGED; BETA-GALACTOSIDASE; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; KIDNEY TUBULES, PROXIMAL; MALE; MIDDLE AGED; TACROLIMUS; TIME FACTORS; YOUNG ADULT;

EID: 67249119488     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.01.116     Document Type: Article

References (27)

1. Schreiber S.L. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251 (1991) 283
2. Jiang H., and Kobayashi M. Differences between cyclosporin A and tacrolimus in organ transplantation. Transplant Proc 31 (1999) 1978
3. Thomson A.W., Bonham C.A., and Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 17 (1995) 584
4. Mergeiter R. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in renal transplantation: a randomised multicenter study. Lancet 359 (2002) 741
5. Woodward R.S., Kutinova A., Schnitzler M.A., et al. Renal graft survival and calcineurin inhibitor. Transplantation 80 (2005) 629
6. Olyaei A.J., de Mattos A.M., and Bennett W.M. Immunosuppressant-induced nephropathy. Drug Safety 21 (1999) 471
7. Hernandez-Herrera G., Del Castillo D., Perez R., et al. Tacrolimus rescue therapy for cyclosporine-induced nephrotoxicity. Transpl Int 11 (1998) 104
8. Chamienia A., Biedunkiewicz B., Król E., et al. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus. Transplant Proc 38 (2006) 81
9. Muirhead N., House A., Hollomby D.J., et al. A comparison between cyclosporine and tacrolimus-based immunosuppression for renal allografts: renal function and blood pressure after 5 years. Transplant Proc 35 (2003) 2391
10. Roos-van Groningen M.C., Scholten E.M., Lelieveld P.M., et al. Molecular comparison of calcineurine inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol 17 (2006) 881
11. Nankivell B.J., and Chapman J.R. Chronic allograft nephropathy: current concepts and future directions. Transplantation 81 (2006) 643
12. Chkhotua A., Shohat M., Tobar A., et al. Replicative senescence in organ transplantation: mechanisms and significance. Transpl Immunol 9 (2002) 165
13. Yates P.J., and Nicholson M.L. The aetiology and pathogenesis of chronic allograft nephropathy. Transpl Immunol 16 (2006) 148
14. Tataranni G., Zavagli G., Farinelli R., et al. Usefulness of the assessment of urinary enzymes and microproteins in monitoring ciclosporin nephrotoxicity. Nephron 60 (1992) 314
15. Bornstein B., Arenas J., Morales J.M., et al. Cyclosporine nephrotoxicity and rejection crisis: diagnosis by urinary enzyme excretion. Nephron 72 (1996) 402
16. Kuzniar J., Marchewka Z., Krasnowski R., et al. Enzymuria and low molecular weight protein excretion as the differentiating marker of complications in the early post kidney transplantation period. Int Urol Nephrol 38 (2006) 753
17. Jung K., Mattenheimer H., and Burchardt U. Urinary enzymes in Clinical and Experimental Medicine (1992), Springer-Verlag AG, Berlin, Germany
18. Cobben N.M., Drent M., De Vries J., et al. Serum β-glucuronidase activity in a population of ex-coalminers. Clin Biochem 32 (1999) 659
19. Haschen R.J. Enzymodiagnostic (1970), VEB Gustaw Fischer, Jena
20. Kuzniar J., Marchewka Z., Lembas-Bogaczyk J., et al. Etiology of increased enzymuria in different morphological forms of glomerulonephritis. Nephron Physiol 98 (2004) 8
21. Forrest M.J., Jewell M.E., Koo G.C., et al. FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leucocyte degranulation. Biochem Pharmacol 42 (1991) 1221
22. Loertscher R., Scholer A., and Burnner F. Clinical relevance of N-acetylglucosaminidase determination in urine of kidney transplant recipients with and without cyclosporin A. Schweiz Med Wochenschr 112 (1982) 1658
23. Knoll G.A., and Bell R.C. Tacrolimus versus cyclosporin for immunosupresion in renal transplantation: meta-analysis of randomized trials. Br Med J 318 (1999) 1104
24. Martins L., Ventura A., Branco A., et al. Cyclosporine versus tacrolimus in kidney transplantation: are there differences in nephrotoxicity?. Transplant Proc 36 (2004) 877
25. Bone J.M., Amara A.B., Shenkin A., et al. Calcineurin inhibitors and proximal renal tubular injury in renal transplant patients with proteinuria and chronic allograft nephropathy. Transplantation 79 (2005) 119
26. Williams D., and Haraqsim L. Calcineurin nephrotoxicity. Adv Chronic Kidney Dis 13 (2006) 47
27. Morales J.M., Andres A., Dominguez-Gil B., et al. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the Tacrolimus Versus Cyclosporine A European Multicentric Study in Kidney Transplant Patients. Transplant Proc 37 (2005) 3738